Evidence map›Paper›PMID 28213364›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Dana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, Ronald F Tutrone, Joshi J Alumkal, Charles J Ryan, Mansoor Saleh, Ralph J Hauke, Rajesh Bandekar, Edna Chow Maneval and 3 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Trial
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Deubiquitination in prostate cancer progression: role of USP22.Journal of cancer metastasis and treatment · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dana E RathkopfSidney Kimmel Center for Prostate and Urologic Cancers, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. Rathkopd@mskcc.org.
Emmanuel S AntonarakisSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Neal D ShoreCarolina Urologic Research Center, Myrtle Beach, South Carolina.
Ronald F TutroneChesapeake Urologic Research Associates, Baltimore, Maryland.
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Charles J RyanUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Mansoor SalehUniversity of Alabama Comprehensive Cancer Center, Birmingham, Alabama.
Ralph J HaukeNebraska Cancer Specialists, Omaha, Nebraska.
Rajesh BandekarJanssen Research & Development, Philadelphia, Pennsylvania.
Edna Chow ManevalAragon Pharmaceuticals, San Diego, California.
Carla J de BoerJanssen Biologics, B.V., Leiden, the Netherlands.
Margaret K YuJanssen Research & Development, Los Angeles, California.
Howard I ScherSidney Kimmel Center for Prostate and Urologic Cancers, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
NCATS NIH HHS UL1 TR002369NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Abiraterone AcetateAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmHumansMaleMiddle AgedNeoplasm MetastasisPrednisoneProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantThiohydantoinsAbiraterone AcetateapalutamidePrednisoneProstate-Specific AntigenThiohydantoins

Identifiers

PMID28213364
PMCPMC5543693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.